Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL BS "Holy cow- look at the volume, this is a bonafide WIPE OUT "
Watch live stream of Bell ringing tomorrow.
https://livestream.com/nasdaq
Blue skies, my friend.
Anyone who follows the trials here knows that the improvement in the untreated eye was proven to be short lived and unsustained, while gains in visual acuity were sustained in the treated eye.
LOL....It's a good thing Ocata will leapfrog the linear phase progression with a pivotal trial!
Ocata methods never killed embryos....no cancer....and they have much more going on than RPE, RPE is just the most advanced....they also create platelets, mcs complete remission of crohn's for each dog in the 6 dog trial....there is alot more going on than meets the eye.
Interesting to see GE and Ocata together....imagine the possibilities....good neighbors working together!
I guess JVs are dilutive too aren't they, it's just that the dilution comes later, which is preferred.
It is important to note that those who qualify for this study with that classification of injury rarely ever recover B&B function. Our first recipient has this recovery verified. The chance it happens without the scaffold implant are pretty slim.
Excellent post, Chuckanutman!
It is good to take note of that. Given the factual improvements that Ocata's treatment is demonstrating in Phase I/IIa, Institutional investors are taking note. Great company!
Here is a really good reference for the anatomy of the spinal cord and description of injury and functions etc. http://www.travisroyfoundation.org/sci/resources/spinal-cord-injury-levels-classification/
Here is the inclusion criteria from Clinical trials page:
Inclusion Criteria:
Aged 18 - 65 years
AIS A traumatic spinal cord injury (T3-T12/L1) confirmed by neurosurgeon, occurring within past 21 days
Non-penetrating contusion injury no less than 4 mm diameter and limited to 2 contiguous vertebral levels
Good to see more presentations coming up! Time to shine the light on Ocata!
It is facts like these that matter, undeniable facts! Thanks for the good news, thanks for the truth, Rumper!
Nice post, Lasers!
I would say that Pluripotent stem cells from embryo safe source are the gold standard.
I think there is a better chance Ocat sees 10.5 per share before it sees $105. per share
My understanding is that the treatment is to prevent the detached retina, by using RPE injection to bolster that fragile part of the anatomy. Myopia creates this stress on the RPE that leads to the detached retina problem. So I don't think it is directly related to increasing visual acuity. Perhaps that is why that trial has not commenced, hard to create buzz, hard to prove you prevented detached retina.....Well, anyone else have input on this subject?
Scottrade shows NVIVD, but does not show any data. Was able to place a limit buy.
Could the likely hood of Ocata being one of the six be pretty high?
Nothing Hype about Ocat....just great solid results that sound like hype because they are soooo goooood! Thanks for sharing your positive oasis quality messages which seem to be surrounded by mirages of negativity.
Multiply the pps times 4....the pps is the pps at end of day prior to split. (Then divide your number of shares by 4....)
I agree. Comparing or lumping Ocata in with other start up biotech companies is not logical. The fear was that RPE would not engraft and would cause a tumor(s), and would not be safe and would not improve eye sight. These are all like on/off switch type success/failure results. We have only seen the on switch as far as results. If they work they work, Kind of like chocolate on Valentines day.
How much will this medical miracle stock be worth?
Well it is different, the scaffold trial has started and there are good results.
The R/S when this was a sub penny play killed this thing, the uplist didnt do anything at all and the same old talk is still going on. Nothing has changed other than the amount of shares stolen from investors
Well....it's good to have an informed criticism...."sub penny" this stock was not nor ever was a sub penny....."uplist didn't do anything" well that is like saying putting in a foundation hasn't done anything since the house isn't complete......."shares stolen from investors" I'll let someone else comment on this if they like.
INvivo still has Hydrogel as a technology for stemcell applications in its pipline.
So like the Apollo mission to the moon....skyrocket. I get it.
I just do not like that there was not enough interest in the offering.
That is one interpretation, it may be true....but there also is another viewpoint which may be true as well: that Ocata was no longer interested in the offering ...because Ocata is interested in something more advantageous.
Time will tell...
I believe the burn rate is 4-5 million a month.
I don't believe so. Your figures seem a little high..12 to 15 million per quarter does not ring a bell...
From a contrarian point of view, I would rather hear a lot of pessimism rather than optimism about today's news.
As I read the first half of your sentence, I thought the last half would say the opposite for this stock here on the forum...lol
Schwartz presented and confirmed those with optimistic sentiments. The science continues to roll forward. Pushing for reduction or elimination of the immunosuppressive drug routine, noting that these drugs were the most difficult thing for trial participants to put up with, is on their agenda. The eye being naturally immune priviledged area, that makes sense to me.
Thanks for the info, guay and SolarGuy. Yes XSNX is in an intense area. I am happy to see him keep pushing and not give up. That area of Cigs I'm assuming he has some desirable patents, perhaps there could be a way of profiting from that with out having to tool up? Or didn't he have some agreement in place years ago with some production company in Asian region of the world? I wonder what it would take to ramp up that? I do recall the publication of 16% efficiency.
SolarGuy, I think that storage of energy is a big deal going forward. So do you see the subcontracting of that to be an area that XSNX should make a bigger effort towards? Meaning they would receive a percentage of sales. Or do you favor the production of energy storage as an area for XSNX to venture into. If XSNX did, what kind of capital would they need, and is that something they are capable of? I guess a partnership might be best for XSNX with (can't think of the name) a privately held company that you mentioned previously.
I bet the sell them for higher price than the bought them.
I wonder how many hands are involved in this pennyland scheme? To be sure, this one will go up again?
Will we "summit" 4 today?
Good question. I wonder just what does XSNX do, design and subcontract the installation? 45kw. Why don't they name who the job is for?